Key Highlights

  • 29.47% is the pre-market climb for Co-Diagnostics (NASDAQ:CODX), indicated at USD 0.4130 on Tuesday, November 10, 2026, against a calculated prior close of USD 0.3190 that had already sunk far below its October level.
  • Skye Bioscience, Inc. climbed 15.93% to USD 0.7999 and Tempest Therapeutics gained 12.06% to USD 0.4050, and neither move can be linked to a confirmed catalyst in the coverage available.
  • IceCure Medical advanced 11.87% to USD 0.9200 on 14,994 shares, while Innovation Beverage Group added 11.49% to USD 0.8250 after a 3.90% fall on Monday, November 9.
  • Every quote sits under the USD 1.00 Nasdaq minimum bid, and published market values run from USD 2.82 million to USD 7.23 million, so thin trading and dilution are the core dangers.

Co-Diagnostics (NASDAQ:CODX): Gains 29.47% Pre-Market With No Clear Trigger

Co-Diagnostics (NASDAQ:CODX) leads the group, indicated at USD 0.4130 before the open on Tuesday, November 10, 2026. That is 29.47% above a calculated prior close of USD 0.3190, a level roughly 58% beneath the October 14 close of USD 0.7645 (calculated). Published coverage does not identify a driver, and no company announcement dated November 9 or November 10 turned up. For context only, diagnostics small caps can jump on results, grant news, financing or a minimum-bid notice, and a rebound after a steep slide can happen with no news at all. October data put Market Value at USD 4.78 million on 6.25 million shares, or, at the pre-market price, about USD 2.58 million (calculated). Cash stood at USD 3.65 million against a trailing net loss of USD 47.06 million, and the 20-day average Volume was 359,681 shares. Spreads are wide at this price. For Co-Diagnostics (NASDAQ:CODX), share issuance, a possible reverse split and a Reversal at the open are the specific hazards to weigh.

Skye Bioscience, Inc. (NASDAQ:SKYE): Gains 15.93% Pre-Market, Driver Unconfirmed

Skye Bioscience, Inc. (NASDAQ:SKYE) quoted USD 0.7999 before the open, 15.93% above a calculated prior close of USD 0.69 from Monday, November 9. Searches turned up no regulatory filing or company statement dated November 9 or November 10, 2026, so published coverage offers no trigger. The most recent items were an August 14, 2026 transaction agreement with Redx Pharma, which included USD 125 million in financings, and a statement that its Capital covers operations into 2027. In the Phase 2a CBeyond trial, the semaglutide combination produced 13.2% weight loss against 10.25% for semaglutide alone, with p equal to 0.0372. An October 26 snapshot put market value at USD 6.95 million on 4.43 million shares, with a 52-week range of USD 1.50 to USD 13.28, so the quote sits below that band (calculated). The share count may have moved and remains unverified. For Skye Bioscience, Inc. (NASDAQ:SKYE), Nasdaq minimum-bid rules, dilution and a reversal at the open are the main risks.

Tempest Therapeutics (NASDAQ:TPST): Rises 12.06% Pre-Market, Trigger Not Found

Tempest Therapeutics (NASDAQ:TPST) was indicated at USD 0.4050 before the open, a rise of USD 0.0436 against a calculated prior close of USD 0.3614. Two searches returned no release, filing or news story dated November 9 or November 10, 2026, leaving the gain without a visible trigger. For general context, a stock far below USD 1.00 can rebound on short covering or a thin order book, and 30 straight Business days of trading beneath the Nasdaq minimum bid results in a deficiency notice. Published figures put market value at USD 7.23 million on 20.00 million shares, with a 52-week range of USD 0.36 to USD 9.75, leaving the quote 95.8% below the high (calculated). Pre-market volume reached only 5,451 shares against an average of 2.55 million. The latest cash figure was USD 779,000 and could be out of date, so dilution is the principal danger for Tempest Therapeutics (NASDAQ:TPST). Spreads may be wide, and a handful of trades can shift the indication by several points.

IceCure Medical (NASDAQ:ICCM): Climbs 11.87% Before the Open, Cause Unclear

IceCure Medical (NASDAQ:ICCM) traded at USD 0.9200 before the open, up 11.87% against a calculated prior close of USD 0.8224. Two checks found no filing or announcement dated November 9 or November 10, 2026, so the move lacks a confirmed trigger. Earlier coverage linked a one-day surge of 203% to a 70% rise in US uptake of the ProSense cryoablation system. That is background rather than an explanation for Tuesday. Published data puts market value at USD 2.82 million on 3.43 million shares, with a 52-week range of USD 0.65 to USD 22.50. Trailing Revenue of USD 3.95 million places the stock near 0.8 times sales (calculated), although the company still loses money. Volume reached 14,994 shares against an average of 154.15 thousand. Offerings, a bid-price notice below USD 1.00 and a reversal at the open are the hazards for IceCure Medical (NASDAQ:ICCM).

Innovation Beverage Group (NASDAQ:IBG): Up 11.49% Before the Open With No Trigger Found

Innovation Beverage Group (NASDAQ:IBG) was indicated at USD 0.8250 before the open, 11.49% above a Monday close of USD 0.7400, which had itself dropped 3.90%. Two lookups produced nothing from November 9 or 10, 2026 in the way of company statements, so no trigger is confirmed. Background items include a Merger announcement with BlockFuel Energy on February 12, 2026, which one published summary valued at USD 220 million to USD 343 million, and a USD 6 million offering that closed in March 2026. Whether the merger has been completed was not verified. Published figures show a market value of USD 3.123 million and a 52-week range of USD 0.7100 to USD 15.8000. Monday volume came to 29,216 shares against an average of 136,367, roughly 21.4% of normal (calculated). Spreads can be wide at these prices, so the indicated level may not be tradeable in size. For Innovation Beverage Group (NASDAQ:IBG), dilution, merger execution and a possible reversal are the hazards to track.

Where Things Stand

The biggest sub-USD 1.00 gainer before Tuesday's open is Co-Diagnostics at 29.47%, trailed by four other Nasdaq names that rose between 11.49% and 15.93%. They share a price below USD 1.00, a market value of a few million dollars and no confirmed catalyst, so each quote is fragile and any single print is a poor guide to the regular session. Thinly traded pre-market moves can fade at the open, since a few small orders set the level and spreads are wide. This list uses a pre-market data snapshot from November 10, 2026.